Key Takeaways PACB posted Q2 revenues of $39.8M, up 10.4% Y/Y, and an adjusted loss per share beating estimates.Consumables and service revenue grew, while adjusted gross margin rose 100 bps to 38% Y/Y in Q2.Global sales surged in APAC and EMEA; PACB also updated its 2025 revenue outlook to $155M-$165M.Pacific Biosciences of California, Inc. (PACB) , popularly known as PacBio, delivered an adjusted loss per share of 13 cents in second-quarter 2025, narrower than the year-ago adjusted loss of 20 cents per sh ...

MENLO PARK, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2025. Second quarter results: Q2 2025Q2 2024Revenue$39.8 million$36.0 millionInstrument revenue$14.2 million$14.7 millionConsumable revenue$18.9 million$17.0 millionService and other revenue$6.7 million<td style="border-top: solid black 1p ...